The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, St. Vincent's Aged Psychiatry Service, St George's Hospital, Victoria, Australia.
International Psychogeriatrics (Impact Factor: 1.93). 06/2009; 21(4):672-87. DOI: 10.1017/S1041610209009405
Source: PubMed


The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer's disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants.
Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning.
A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring.
The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.

Download full-text


Available from: Ashley I Bush, Oct 05, 2015
1 Follower
61 Reads
  • Source
    • "They have been created in and for very specific environments with their own respective emphases and limitations. The driver for the creation of a new alternative approach arose from a series of joint studies between King's College London, the Karolinska Institute, and our collaborators working on a number of large imaging studies including AddNeuroMed (Lovestone et al., 2007, 2009), Alzheimer Disease Neuroimaging Initiative (ADNI; Jack et al., 2008; Weiner et al., 2010), and AIBL (Ellis et al., 2009). The hive database system (theHiveDB) has been developed to match requirements not easily reconciled with the alternatives mentioned above. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hive database system (theHiveDB) is a web-based brain imaging database, collaboration, and activity system which has been designed as an imaging workflow management system capable of handling cross-sectional and longitudinal multi-center studies. It can be used to organize and integrate existing data from heterogeneous projects as well as data from ongoing studies. It has been conceived to guide and assist the researcher throughout the entire research process, integrating all relevant types of data across modalities (e.g., brain imaging, clinical, and genetic data). TheHiveDB is a modern activity and resource management system capable of scheduling image processing on both private compute resources and the cloud. The activity component supports common image archival and management tasks as well as established pipeline processing (e.g., Freesurfer for extraction of scalar measures from magnetic resonance images). Furthermore, via theHiveDB activity system algorithm developers may grant access to virtual machines hosting versioned releases of their tools to collaborators and the imaging community. The application of theHiveDB is illustrated with a brief use case based on organizing, processing, and analyzing data from the publically available Alzheimer Disease Neuroimaging Initiative.
    Frontiers in Neuroinformatics 01/2014; 7(4):49. DOI:10.3389/fninf.2013.00049 · 3.26 Impact Factor
  • Source
    • "Premorbid intelligence was estimated using the Wechsler Test of Adult Reading (WTAR); depressive and anxiety symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS); subjective memory impairment was measured using the Memory Complaint Questionnaire (MAC-Q); and levels of physical activity were measured using the International Physical Activity Questionnaire (IPAQ). All participants underwent extensive medical, psychiatric, and neuropsychological assessments and neuroimaging after enrollment, and at 18 and 36 months after baseline (Ellis et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)-related cognitive impairment. We aimed to determine the relationship between BDNF Val66Met and beta-amyloid (Aβ) on cognitive decline, hippocampal atrophy, and Aβ accumulation over 36 months in 165 healthy adults enrolled in the Australian Imaging, Biomarkers and Lifestyle study. In healthy adults with high Aβ, Met carriers showed significant and moderate-to-large declines in episodic memory, executive function, and language, and greater hippocampal atrophy over 36 months, compared with Val/Val homozygotes. BDNF Val66Met was not found to be related to rates of change in cognition or hippocampal volume in healthy adults with low Aβ. BDNF Val66Met did not relate to the amount of Aβ or to the rate of Aβ accumulation in either group. High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD.
    Neurobiology of Aging 11/2013; 34(11):2457-64. DOI:10.1016/j.neurobiolaging.2013.05.006 · 5.01 Impact Factor
  • Source
    • "The AIBL study incorporates longitudinal neuroimaging , biomarker, neuropsychometric, and lifestyle data, see [37] for a detailed description of methods. Briefly, participants over the age of 65 years and fluent in English were divided into three groups; cognitively healthy individuals (HC), participants with mild cognitive impairment (MCI) based on the established criteria [38] [39], and participants diagnosed with possible or probable AD as defined by NINCDS-ADRDA criteria [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the leading cause of dementia and represents a significant burden on the global economy and society. The role of transition metals, in particular copper (Cu), in AD has become of significant interest due to the dyshomeostasis of these essential elements, which can impart profound effects on cell viability and neuronal function. We tested the hypothesis that there is a systemic perturbation in Cu compartmentalization in AD, within the brain as well as in the periphery, specifically within erythrocytes. Our results showed that the previously reported decrease in Cu within the human frontal cortex was confined to the soluble (P < 0.05) and total homogenate (P < 0.05) fractions. No differences were observed in Cu concentration in erythrocytes. Our data indicate that there is a brain specific alteration in Cu levels in AD localized to the soluble extracted material, which is not reflected in erythrocytes. Further studies using metalloproteomics approaches will be able to elucidate the metabolic mechanism(s) that results in the decreased brain Cu levels during the progression of AD.
    International Journal of Alzheimer's Disease 10/2013; 2013:623241. DOI:10.1155/2013/623241
Show more